KDR and lung cancer: Furthermore, evidence from the use of VEGFR2 spectrum multi-targeting TKI sitravatinib in combination with nivolumab in the lung cancer patients who developed resistance to anti-PD1 therapy also indicates immune-modulation effect from VEGF targeting [20].